Predictive Oncology Yönetim

Yönetim kriter kontrolleri 4/4

Predictive Oncology CEO'su Raymond Vennare, Nov2022 tarihinde atandı, in görev süresi 3.17 yıldır. in toplam yıllık tazminatı $ 525.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler $ 5.37K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 3.8 yıldır.

Anahtar bilgiler

Raymond Vennare

İcra Kurulu Başkanı

US$525.0k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	2yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

CEO Tazminat Analizi

Raymond Vennare'un ücretlendirmesi Predictive Oncology'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$525k	US$525k	-US$14m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$639k	US$88k	-US$26m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$33k	n/a	-US$20m

Tazminat ve Piyasa: Raymond 'ın toplam tazminatı ($USD 525.00K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 647.72K ).

Tazminat ve Kazançlar: Raymond 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Raymond Vennare (71 yo)

2yrs

Görev süresi

US$525,000

Tazminat

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Raymond Vennare	CEO & Chairman	2yrs	US$525.00k	0.11% $ 5.4k
Joshua Blacher	Interim Chief Financial Officer	1.2yrs	Veri yok	Veri yok
Theresa Ferguson	Senior Director of Marketing	2.6yrs	Veri yok	Veri yok
Lawrence DeLucas	Senior Vice President of Biologics	no data	Veri yok	Veri yok
Arlette Uihlein	Senior VP of Translational Medicine & Drug Discovery and Medical Director	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: POAI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Raymond Vennare	CEO & Chairman	3.2yrs	US$525.00k	0.11% $ 5.4k
Bernard Harris	Member of Business Advisory Board	1.4yrs	Veri yok	Veri yok
Charles Nuzum	Lead Independent Director	4.3yrs	US$98.90k	Veri yok
Andrew Einhorn	Member of Business Advisory Board	1.4yrs	Veri yok	Veri yok
Veena Rao-Mirmira	Independent Director	1.5yrs	US$73.34k	0.14% $ 6.9k
Marc Malandro	Member of Scientific Advisory Board	6.2yrs	Veri yok	Veri yok
Daniel Handley	Independent Director	4.8yrs	US$54.45k	0.28% $ 14.1k
Robert Murphy	Member of Scientific Advisory Board	6.2yrs	Veri yok	Veri yok
Matthew Hawryluk	Independent Director	2yrs	US$65.56k	0.14% $ 7.2k
Nancy Chung-Welch	Independent Director	4.3yrs	US$76.67k	0.32% $ 16.0k
Gregory St. Clair	Independent Director	4.3yrs	US$65.56k	0.34% $ 17.0k
Christoph Reinhard	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: POAI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Predictive Oncology Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

High number of new and inexperienced directors

Recent updates

Predictive Oncology Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Predictive Oncology Inc. Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.98 loss in 2Q 2023)

Predictive Oncology Inc. Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Inc. to Report Q2, 2024 Results on Aug 14, 2024

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Share price stability

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.86 loss in 1Q 2023)

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Share price stability

New major risk - Market cap size

Full year 2023 earnings released: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$1.04 loss in 3Q 2022)

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$3.02 loss in 2Q 2022)

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

First quarter 2023 earnings released: US$0.86 loss per share (vs US$1.02 loss in 1Q 2022)

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Price target increased to US$5.00

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology has a new CEO

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Predictive Oncology announces retirement of CEO Mel Engle

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought US$62k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$4.50

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

CEO & Director Carl Schwartz has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study